Batalov Artem I, Goryaynov Sergey A, Zakharova Natalya E, Solozhentseva Kristina D, Kosyrkova Alexandra V, Potapov Alexander A, Pronin Igor N
N. N. Burdenko National Medical Research Center of Neurosurgery of the Ministry of Health of the Russian Federation, 125047 Moscow, Russia.
J Clin Med. 2021 May 28;10(11):2387. doi: 10.3390/jcm10112387.
The prediction of the fluorescent effect of 5-aminolevulinic acid (5-ALA) in patients with diffuse gliomas can improve the selection of patients. The degree of enhancement of gliomas has been reported to predict 5-ALA fluorescence, while, at the same time, rarer cases of fluorescence have been described in non-enhancing gliomas. Perfusion studies, in particular arterial spin labeling perfusion, have demonstrated high efficiency in determining the degree of malignancy of brain gliomas and may be better for predicting fluorescence than contrast enhancement. The aim of the study was to investigate the relationship between tumor blood flow, measured by ASL, and intraoperative fluorescent glow of gliomas of different grades.
Tumoral blood flow was assessed in 75 patients by pCASL (pseudo-continuous arterial spin labeling) within 1 week prior to surgery. In all cases of tumor removal, 5-ALA had been administered preoperatively. Maximum values of tumoral blood flow (TBF max) were measured, and normalized tumor blood flow (nTBF) was calculated.
A total of 76% of patients had significant contrast enhancement, while 24% were non-enhancing. The histopathology revealed 17 WHO grade II gliomas, 12 WHO grade III gliomas and 46 glioblastomas. Overall, there was a relationship between the degree of intraoperative tumor fluorescence and ASL-TBF (R = 0.28, = 0.02 or the TBF; R = 0.34, = 0.003 for nTBF). Non-enhancing gliomas were fluorescent in 9/18 patients, with nTBF in fluorescent gliomas being 54.58 ± 32.34 mL/100 mg/s and in non-fluorescent gliomas being 52.99 ± 53.61 mL/100 g/s ( > 0.05). Enhancing gliomas were fluorescent in 53/57 patients, with nTBF being 170.17 ± 107.65 mL/100 g/s in fluorescent and 165.52 ± 141.71 in non-fluorescent gliomas ( > 0.05).
Tumoral blood flow levels measured by non-contrast ASL perfusion method predict the fluorescence by 5-ALA; however, the additional value beyond contrast enhancement is not clear. ASL is, however, useful in cases with contraindication to contrast.
预测5-氨基乙酰丙酸(5-ALA)在弥漫性胶质瘤患者中的荧光效应有助于优化患者选择。据报道,胶质瘤的强化程度可预测5-ALA荧光,与此同时,非强化胶质瘤中也有罕见的荧光病例报道。灌注研究,尤其是动脉自旋标记灌注,已证明在确定脑胶质瘤恶性程度方面具有高效性,并且在预测荧光方面可能比对比增强更好。本研究旨在探讨通过动脉自旋标记(ASL)测量的肿瘤血流与不同级别胶质瘤术中荧光之间的关系。
在75例患者手术前1周内,采用伪连续动脉自旋标记(pCASL)评估肿瘤血流。在所有肿瘤切除病例中,术前均已给予5-ALA。测量肿瘤血流最大值(TBF max),并计算标准化肿瘤血流(nTBF)。
共有76%的患者有明显的对比增强,24%为非强化。组织病理学显示17例世界卫生组织(WHO)II级胶质瘤、12例WHO III级胶质瘤和46例胶质母细胞瘤。总体而言,术中肿瘤荧光程度与ASL-TBF之间存在相关性(R = 0.28,P = 0.02对应TBF;R = 0.34,P = 0.003对应nTBF)。18例非强化胶质瘤患者中有9例出现荧光,荧光胶质瘤的nTBF为54.58±32.34 mL/100 mg/s,非荧光胶质瘤为52.99±53.61 mL/100 g/s(P>0.05)。57例强化胶质瘤患者中有53例出现荧光,荧光胶质瘤的nTBF为170.17±107.65 mL/100 g/s,非荧光胶质瘤为165.52±141.71 mL/100 g/s(P>0.05)。
通过非对比ASL灌注法测量的肿瘤血流水平可预测5-ALA荧光;然而,对比增强之外的附加价值尚不清楚。不过,ASL在有对比禁忌的情况下很有用。